News and Announcements
GSK reports regulatory progress for Omjjara, Jemperli
By Josh White
Date: Monday 24 Jun 2024
(Sharecast News) - GSK announced on Monday that it has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for 'Omjjara', or momelotinib, as a treatment for myelofibrosis.
The FTSE 100 pharmaceuticals giant described Omjjara is a once-daily, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
Article Archive
You are here: news
